Last reviewed · How we verify
SM03
SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation.
SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation. Used for Systemic lupus erythematosus (SLE), Autoimmune conditions.
At a glance
| Generic name | SM03 |
|---|---|
| Sponsor | SinoMab BioScience Ltd |
| Drug class | CD40 ligand inhibitor (monoclonal antibody) |
| Target | CD40L (CD154) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
SM03 binds to CD40 ligand, a key costimulatory molecule involved in T cell-dependent B cell activation and immune cell interactions. By blocking CD40L, the drug suppresses pathogenic immune responses and reduces inflammatory cytokine production. This mechanism is intended to treat autoimmune and inflammatory conditions where CD40L-mediated signaling drives disease pathology.
Approved indications
- Systemic lupus erythematosus (SLE)
- Autoimmune conditions
Common side effects
- Infection
- Infusion-related reactions
- Immunosuppression-related events
Key clinical trials
- A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis (PHASE1)
- A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX (PHASE3)
- A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SM03 CI brief — competitive landscape report
- SM03 updates RSS · CI watch RSS
- SinoMab BioScience Ltd portfolio CI